Vincristine Intravenous and Myelosuppression
Result of checking the interaction of drug Vincristine Intravenous and disease Myelosuppression for safety when used together.
When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.
Consumer:Vincristine induces dose-related myelosuppression. Leukopenia, thrombocytopenia, and anemia have been reported, however vincristine does not appear to have a consistent or significant effect on platelets or red blood cells. Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding. Therapy with vincristine should be administered cautiously in patients with compromised bone marrow reserve. Monitor complete blood counts prior to each dose. If Grade 3 or 4 neutropenia, thrombocytopenia, or anemia develops, consider a dose modification or reduction as well as supportive care measures.
- Chong CD Logothetis CJ Savaraj N Fritsche HA Gietner AM Samuels ML "The correlation of vinblastine pharmacokinetics to toxicity in testicular cancer patients." J Clin Pharmacol 28 (1988): 714-8
- "Product Information. Oncovin (vincristine)." Lilly, Eli and Company, Indianapolis, IN.
- Neville AJ Rand CA Barr RD "Vinblastine-induced erythrocytotoxicity." Scand J Haematol 28 (1982): 32-8
- Young JA, Howell SB, Green MR "Pharmacokinetics and toxicity of 5-day continuous infusion of vinblastine." Cancer Chemother Pharmacol 12 (1984): 43-5
Generic Name: vincristine
Brand Name: Oncovin, Vincasar PFS
Synonyms: Vincristine, VinCRIStine